Genmab — December 2017
-
Fik vi nogensinde fulgt op på ADCT301? For the 27 response-evaluable patients with HL in Part 1, treated at doses greater than or equal to 45 µg/kg, the ORR was 77 percent (21/27 patients) with 12 patients achieving a complete response (44 percent) and 9 patients achieving a partial response (33 percent).
-
For the 12 response-evaluable patients with HL in Part 1 and Part 2, treated at the 45 µg/kg dose, the ORR was 100 percent (12/12) with 6 patients achieving a complete response (50 percent) and 6 patients achieving a partial response (50 percent).
-
Det er 'gammelt nyt' fra 11 dec. http://adctherapeutics.com/
-
Godt nytår til alle, og en kæmpe tak til de utroligt dygtige skribenter der har en fantastisk viden inden for dette område.Jeg har været med i mange år i Genmab, og det har været en fantastisk rejse.For mange år siden så jeg en vidieo her på siden, hvor det sidste spørgsmål var til personen var hvilken Biotek aktie af de danske ville få et internationalt gennembrud ville være.Han var ikke i tvivl Genmab. Hvorfor? Fordi de var fuldstændig ligeglade med hvad deres løn
-
Yes, he is clearly an optimist. He has also been following the stock from the very beginning, when he was working for Mr Stienstra, who you may remember was the largest private shareholder at some time. I assume he reads Proinvestor, maybe he can write an english version one of these days
-
Jeg takker også dette forum med alle dets skribenter, det gør at jeg tør holde ved. Godt nytår til jer alle.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind